Literature DB >> 12694228

The natural history of sclerosteosis.

H Hamersma1, J Gardner, P Beighton.   

Abstract

Sclerosteosis (SCL) is a severe, progressive, autosomal-recessive craniotubular hyperostosis (MIM 269500). The determinant gene (SOST) has been isolated, and genotype-phenotype correlations, as well as the elucidation of pathogenetic mechanisms, are dependent upon the documentation of the natural history of the condition. For this reason, the course and complications in 63 affected individuals in South Africa, seen over a 38-year period, have been analyzed. Thirty-four of these persons died during the course of the survey, 24 from complications related to elevation of intracranial pressure as a result of calvarial overgrowth. The mean age of death in this group of individuals was 33 years, with an even gender distribution. Facial palsy and deafness, as a result of cranial nerve entrapment, developed in childhood in 52 (82%) affected persons. Mandibular overgrowth was present in 46 (73%) adults and syndactyly in 48 (76%). In South Africa in 2002, 29 affected persons were alive, 10 being < or =20 years of age. It is evident that sclerosteosis is a severe disorder which places a considerable burden upon affected individuals and their families. Copyright Blackwell Munksgaard, 2003

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694228     DOI: 10.1034/j.1399-0004.2003.00036.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  56 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.

Authors:  Gill Holdsworth; Patrick Slocombe; Carl Doyle; Bernadette Sweeney; Vaclav Veverka; Kelly Le Riche; Richard J Franklin; Joanne Compson; Daniel Brookings; James Turner; Jeffery Kennedy; Rachael Garlish; Jiye Shi; Laura Newnham; David McMillan; Mariusz Muzylak; Mark D Carr; Alistair J Henry; Thomas Ceska; Martyn K Robinson
Journal:  J Biol Chem       Date:  2012-06-13       Impact factor: 5.157

3.  Bone metabolic activity in hyperostosis cranialis interna measured with 18F-fluoride PET.

Authors:  Jérôme J Waterval; Thijs M A Van Dongen; Robert J Stokroos; Jaap G J Teule; Gerrit J Kemerink; Boudewijn Brans; Fred H M Nieman; Johannes J Manni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-16       Impact factor: 9.236

Review 4.  Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 5.  Sclerostin and skeletal health.

Authors:  Maryam Sharifi; Lisa Ereifej; E Michael Lewiecki
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

6.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

7.  Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.

Authors:  Vaclav Veverka; Alistair J Henry; Patrick M Slocombe; Andrew Ventom; Barbara Mulloy; Frederick W Muskett; Mariusz Muzylak; Kevin Greenslade; Adrian Moore; Li Zhang; Jianhua Gong; Xueming Qian; Chris Paszty; Richard J Taylor; Martyn K Robinson; Mark D Carr
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

Review 8.  Fracture healing: mechanisms and interventions.

Authors:  Thomas A Einhorn; Louis C Gerstenfeld
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

Review 9.  Osteoporosis treatment: recent developments and ongoing challenges.

Authors:  Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-07-07       Impact factor: 32.069

10.  Osteoblasts as leukemia-initiating cells.

Authors:  Benjamin J Frisch; Laura M Calvi
Journal:  Bonekey Rep       Date:  2014-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.